Boucherie Quentin, Rouby Franck, Frankel Diane, Roll Patrice, Micallef Joelle
Department of clinical pharmacology and pharmacovigilance, regional pharmacovigilance centre of Marseille Provence Corse, Assistance publique-Hôpitaux de Marseille, 270, boulevard Sainte-Marguerite, 13009 Marseille, France; Inserm 1106, Aix-Marseille université, institut des neurosciences des systèmes, 13005 Marseille, France.
Department of clinical pharmacology and pharmacovigilance, regional pharmacovigilance centre of Marseille Provence Corse, Assistance publique-Hôpitaux de Marseille, 270, boulevard Sainte-Marguerite, 13009 Marseille, France.
Therapie. 2018 Oct;73(5):385-388. doi: 10.1016/j.therap.2018.03.001. Epub 2018 Mar 7.
Because national data on proton pump inbibitors (PPIs) consumption in France are scarce and because there is a growing literature on potential adverse drug reaction induced by this pharmacological class, we would like to more describe the main evolution of PPI use and the main characteristics of its users in France. We used a 1/97th representative sample of beneficiaries of the French health insurance called "échantillon généraliste des bénéficiaires" (EGB) to describe PPIs' use over time (duration of use by year) from 2006 to 2016. In 2016, 108,249 patients had at least 1 dispensing of PPI (i.e. 19.5% of EGB versus 16.5% in 2006). The part of patients with only 1 reimbursement of PPI by years decreased from 43.9% in 2006 to 39.0% in 2016. Among the patient with at least 2 PPI dispensing/years, the mean number of dispensing increased from 6.2±4.2 in 2006 to 6.9 in 2016. The over 75 year's old group is particularly concerned by the increase in both duration and dosage over the period of study, as mean DDD per year increased by 31% and mean number of dispensing per year by 17% from 2006 to 2016. Based on these results, PPI users could almost represent 11 million peoples in France (13 million on a whole population) in 2016. Initiatives to assess the appropriateness of use of these drugs might be warranted.
由于法国关于质子泵抑制剂（PPI）消费的全国性数据匮乏，且关于这一药物类别引发的潜在药物不良反应的文献日益增多，我们希望更详细地描述法国PPI使用的主要演变情况及其使用者的主要特征。我们使用了法国医疗保险受益人的1/97代表性样本，即“受益人的全科样本”（EGB），来描述2006年至2016年期间PPI的使用情况（逐年使用时长）。2016年，108,249名患者至少有1次PPI配药（即占EGB的19.5%，而2006年为16.5%）。每年仅报销1次PPI的患者比例从2006年的43.9%降至2016年的39.0%。在每年至少有2次PPI配药的患者中，平均配药次数从2006年的6.2±4.2次增加到2016年的6.9次。在研究期间，75岁以上人群在使用时长和剂量方面的增长尤为显著，从2006年到2016年，每年的限定日剂量（DDD）平均增加了31%，每年的平均配药次数增加了17%。基于这些结果，2016年法国PPI使用者可能接近1100万人（占总人口1300万）。或许有必要采取举措评估这些药物使用的合理性。
